Therapeutic Compatibility of Orally Administered Racemic Ketamine with Modafinil, a CYP3A4 Enzyme Inducer, in Treatment-Refractory Major Depressive Disorder.
作者信息
Andrade Chittaranjan
机构信息
Dept. of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.
出版信息
Indian J Psychol Med. 2023 Nov;45(6):651-653. doi: 10.1177/02537176231160264. Epub 2023 Mar 29.
Abstract
摘要
相似文献
1
Therapeutic Compatibility of Orally Administered Racemic Ketamine with Modafinil, a CYP3A4 Enzyme Inducer, in Treatment-Refractory Major Depressive Disorder.口服消旋氯胺酮与CYP3A4酶诱导剂莫达非尼在难治性重度抑郁症治疗中的治疗相容性。
Indian J Psychol Med. 2023 Nov;45(6):651-653. doi: 10.1177/02537176231160264. Epub 2023 Mar 29.
2
Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil.利用人血浆来源的小细胞外囊泡作为液体活检来研究莫达非尼对细胞色素P450 3A4的诱导作用。
Clin Pharmacol Ther. 2022 Feb;111(2):425-434. doi: 10.1002/cpt.2440. Epub 2021 Nov 2.
3
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.加拿大心境与焦虑治疗网络（CANMAT）成人重性抑郁障碍使用消旋卡前列甲酯治疗工作组推荐：加拿大心境与焦虑治疗网络（CANMAT）成人重性抑郁障碍使用消旋卡前列甲酯治疗工作组推荐。
Can J Psychiatry. 2021 Feb;66(2):113-125. doi: 10.1177/0706743720970860. Epub 2020 Nov 11.
4
Compounded intranasal racemic ketamine for major depressive disorder: A case report.复方鼻内消旋氯胺酮治疗重度抑郁症：一例报告。
Exp Clin Psychopharmacol. 2021 Dec;29(6):750-754. doi: 10.1037/pha0000437. Epub 2021 Mar 4.
5
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.一项随机、交叉比较氯胺酮与电抽搐治疗重性抑郁发作的研究：加拿大抑郁症生物标志物整合网络研究方案。
BMC Psychiatry. 2020 Jun 2;20(1):268. doi: 10.1186/s12888-020-02672-3.
6
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.治疗抵抗性抑郁症患者使用消旋体氯胺酮和 Esketamine 输注后抑郁症状缓解和应答的临床预测因子。
Hum Psychopharmacol. 2022 Jul;37(4):e2836. doi: 10.1002/hup.2836. Epub 2022 Feb 18.
7
Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.健康受试者中阿得拉非尼与经细胞色素P450酶1A2、3A4和2C19代谢的药物的相互作用情况。
Clin Pharmacokinet. 2008;47(1):61-74. doi: 10.2165/00003088-200847010-00006.
8
Effects of medetomidine and its active enantiomer dexmedetomidine on N-demethylation of ketamine in canines determined in vitro using enantioselective capillary electrophoresis.使用对映体选择性毛细管电泳体外测定美托咪定及其活性对映体右美托咪定对犬体内氯胺酮N-去甲基化的影响。
Electrophoresis. 2015 Nov;36(21-22):2703-2712. doi: 10.1002/elps.201500147. Epub 2015 Aug 20.
9
Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).消旋体氯胺酮作为单相抑郁电抽搐治疗的替代疗法：一项随机、开放标签、非劣效性试验（KetECT）。
Int J Neuropsychopharmacol. 2022 May 27;25(5):339-349. doi: 10.1093/ijnp/pyab088.
10
Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.静脉注射消旋氯胺酮与鼻腔内依他佐辛、阿立哌唑和锂盐作为增效治疗难治性单相抑郁的疗效、耐受性和可接受性比较：系统评价和网络荟萃分析。
J Affect Disord. 2024 Feb 1;346:49-56. doi: 10.1016/j.jad.2023.11.023. Epub 2023 Nov 8.
引用本文的文献
1
A systematic scoping review of Indian literature on ketamine use for treating psychiatric disorders.关于氯胺酮用于治疗精神疾病的印度文献的系统综述。
Ind Psychiatry J. 2025 May-Aug;34(2):167-178. doi: 10.4103/ipj.ipj_376_24. Epub 2025 May 22.
本文引用的文献
1
Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant - implications for precision dosing in a global perspective.关于氯胺酮作为抗抑郁药的安全性的遗传药理学和药物相互作用方面——从全球角度看精准用药的意义。
Br J Clin Pharmacol. 2022 Dec;88(12):5149-5165. doi: 10.1111/bcp.15467. Epub 2022 Aug 5.
2
Oral racemic ketamine for common clinical contexts in patients with major depressive disorder: An important intervention that treatment guidelines may never include.口服消旋氯胺酮用于重度抑郁症患者的常见临床情况：一种治疗指南可能从未涵盖的重要干预措施。
Bipolar Disord. 2022 Mar;24(2):113-114. doi: 10.1111/bdi.13155. Epub 2021 Nov 23.
3
Oral Ketamine for Depression, 2: Practical Considerations.口腔用氯胺酮治疗抑郁症 2：实际考虑因素。
J Clin Psychiatry. 2019 Apr 9;80(2):19f12838. doi: 10.4088/JCP.19f12838.
4
Metabolism and metabolomics of ketamine: a toxicological approach.氯胺酮的代谢与代谢组学：一种毒理学方法。
Forensic Sci Res. 2017 Feb 20;2(1):2-10. doi: 10.1080/20961790.2017.1285219. eCollection 2017.
5
An update on the role of intestinal cytochrome P450 enzymes in drug disposition.肠道细胞色素P450酶在药物处置中作用的最新进展。
Acta Pharm Sin B. 2016 Sep;6(5):374-383. doi: 10.1016/j.apsb.2016.07.012. Epub 2016 Aug 4.
6
Cytochrome P450-mediated metabolism in the human gut wall.细胞色素P450介导的人体肠壁代谢。
J Pharm Pharmacol. 2009 May;61(5):541-58. doi: 10.1211/jpp/61.05.0002.
7
Intestinal first-pass metabolism of CYP3A4 substrates.细胞色素P450 3A4底物的肠道首过代谢。
Drug Metab Pharmacokinet. 2008;23(2):87-94. doi: 10.2133/dmpk.23.87.
8
Clinical pharmacokinetic profile of modafinil.莫达非尼的临床药代动力学特征。
Clin Pharmacokinet. 2003;42(2):123-37. doi: 10.2165/00003088-200342020-00002.
Zotero 插件